期刊
FRONTIERS IN CELLULAR NEUROSCIENCE
卷 15, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fncel.2021.716747
关键词
experimental autoimmune encephalomyelitis; multiple sclerosis; T cells; programmed cell death ligand-1; programmed cell death protein-1
资金
- General Program of the National Natural Science Foundation of China [81671177]
- Natural Science Foundation of Jilin Province Science and Technology Development Plan Project [20190201043JC]
- Key Research and Development Project of Social Development Division of Jilin Science and Technology Department [20200403109SF]
- Special Project for Health Professionals of Jilin Provincial Finance Department [JLSWSRCZX20200056]
- Swedish Research Council [2015-03005]
- Jilin University of China
- Swedish Research Council [2015-03005] Funding Source: Swedish Research Council
The PD-1/PD-L1 axis plays a crucial role in multiple sclerosis (MS), and understanding the complex relationship between them may expand our knowledge of therapeutic approaches.
The programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) axis is a widely studied immune checkpoint that modulates signaling pathways related to T cell activation. The use of PD-1/PD-L1 inhibitors is a promising immune therapy strategy for cancer patients. However, individuals treated with PD-1/PD-L1 inhibitors may develop immune-related adverse events due to excessive immune reactions. Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease of the central nervous system. T cells and the PD-1/PD-L1 axis play vital roles in the pathogenesis of MS. A better understanding of the complex relationship between the PD-1/PD-L1 axis and T cells may extend our knowledge of the molecular mechanisms and therapeutic approaches for MS. In this review, we summarize the most recent findings regarding the role of the PD-1/PD-L1 axis in MS and discuss the potential therapeutic strategies to modulate the expression of PD-1/PD-L1 in MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据